Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Ensembl
	HGNC	UniGene	Nucleotide	OMIM	UCSC

Home Page

FLASH GENE

Symbol

CCL3L1

contributors: SGE/npt - updated : 13-07-2010

HGNC name	chemokine (C-C motif) ligand 3-like 1
HGNC id	10628

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

Location	17q12      Physical location : 34.522.267 - 34.625.730
Synonym name	G0/G1 switch regulatory protein 19-2
	tonsillar lymphocyte LD78 beta protein
	small-inducible cytokine A3-like 1
	LD78-beta(1-70)
	C-C motif chemokine 3 like 1
	PAT 464.2
Synonym symbol(s)	LD78, SCYA3L, LD78BETA, MIP-1alpha P, SCYA3L1, D17S1718, G0S19-2, 464.2, MGC12815, MGC104178, MGC182017, MIP1AP, CCL3L3

DNA

TYPE	like-sequence
SPECIAL FEATURE	component of a cluster, head to head, opposite orientation
text	clustered with other C-C cytokines in IMC1@
	head to head oritentation with SCYA4L
STRUCTURE	1.89 kb     3 Exon(s)    1-6 Copie(s)

10 Kb 5' upstream gene genomic sequence study

regulatory sequence	Binding site   transcription factor
motif	repetitive sequence   ALU
text structure	a NF chi B binding site
	a 5'Alu sequence
	in 5' flanking sequence,CK-2 and SRE motifs

MAPPING

cloned

Y

linked

N

status

confirmed

Map	cen - NF1 NF1 - (CCL7 ,CCL2 ,CCL13 ) - Y1741 breakpoint - CCL5 - (CCL3L2 ,CCL4L1 ) - CCL18 - CCL3 - CCL4 - CCL3L1 - CCL4L1 - (CCL15 ,CCL14 )- CCL16 - RARA RARA - qter
Authors	Naruse 96, Modi (2004)

RNA

TRANSCRIPTS	type	messenger

identification nb exons type bp product Protein kDa AA specific expression Year Pubmed NM_021006 3 - 804 NP_066286 - 93 - Nakao (1990)

EXPRESSION

Type	restricted

expressed in	(based on citations)
organ(s)	System Organ level 1 Organ level 2 Organ level 3 Organ level 4 Level Pubmed Species Stage Rna symbol Lymphoid/Immune tonsils         Reproductive female system breast mammary gland

tissue

System Tissue Tissue level 1 Tissue level 2 Level Pubmed Species Stage Rna symbol Blood / hematopoietic bone marrow

cell lineage

cell lines

fluid/secretion

at STAGE

PROTEIN

PHYSICAL PROPERTIES

STRUCTURE

motifs/domains

isoforms

Precursor

HOMOLOGY

interspecies	homolog to murine Ccl3 (76.1pc)
	homolog to rattus Ccl3 (77.2pc)

intraspecies	homolog to SCYA3L2
	paralog to CCL3

Homologene

FAMILY

intercrine beta (chemokine CC) family

CATEGORY

signaling cytokine

SUBCELLULAR LOCALIZATION	extracellular
text	secreted

basic FUNCTION	attracting and activating leukocytes
	having an anti-HIV-1 activity (binding to CCR5 inhibits HIV entry)
	should be a potential chemokine to protect against neuronal injury in HIV-1 gp120-related neuronal toxicity (Chun 2009)
	increased CCL3L1 expression may enhance inflammatory responses and increase the chance of autoimmune disease (McKinney 2008)

CELLULAR PROCESS	cell life, proliferation/growth

PHYSIOLOGICAL PROCESS

immunity/defense , inflammation

PATHWAY

metabolism

signaling

signal transduction

cell-cell signaling, G protein linked receptor signaling pathway

a component

precursor cleaved into two chains LD78-beta (3-70) and LD78-beta (5-70) by proteolytic cleavage after secretion, probably by DPP4

INTERACTION

DNA

RNA

small molecule

protein	binding to CCR3 and CCR5 receptor
	binding to several chemokine receptors including chemokine binding protein 2
	ligand for CCR1

cell & other

REGULATION

Other

LPS stimulation of peripheral blood mononuclear cells increased CCL3L1 expression (Townson 2002)

ASSOCIATED DISORDERS

corresponding disease(s)

Susceptibility

to HIV/acquired immunodeficiency syndrome (AIDS)

Variant & Polymorphism other	a low copy number is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility
	lower CCL3L1 gene copy number compared to the population median is associated with chronic hepatitis C (Grünhage 2010)
	CCR5-59029 AG genotype and CCL3L1 gene dose appear to have synergistic or interactive effects and are expected to be involved in the host innate resistance to HIV-1 infection (Rathore 2009)
	copy number of CCL3L1 influences risk of systemic lupus erythaematosus (SLE) and modifies the SLE-influencing effects associated with the CCR5 genotypes (Mamtani 2008)

Candidate gene
Marker
Therapy target	CCL3L1-CCR5 variations may be useful in identifying patients requireng earlier initiation of highly active antiretroviral therapy (Ahuja 2008)

ANIMAL & CELL MODELS